Patent · US Active

Anti-CD38 antibody and lenalidomide or bortezomib for the treatment of multipe myeloma and NHL

US8877899B2 · kind B2 · utility

13Cited by

3References

19Claims

0Family size

Assignee

MORPHOSYS AG · DE

Inventors

Lisa Rojkjaer · Hedingen, CH
Rainer Boxhammer · Aying, DE
Jan Endell · Munich, DE
Mark Winderlich · Munich, DE
Christofer Samuelsson · Holzkirchen, DE

Key dates

Filing date	Sep 26, 2011
Grant date	Nov 4, 2014
Priority date	—
Expiry date	Sep 26, 2031

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/76
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present disclosure describes a pharmaceutical combination of an anti-CD38 antibody and lenalidomide and a pharmaceutical combination of an anti-CD38 antibody and bortezomib.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.